<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308432">
  <stage>Registered</stage>
  <submitdate>12/10/2009</submitdate>
  <approvaldate>4/11/2009</approvaldate>
  <actrnumber>ACTRN12609000946213</actrnumber>
  <trial_identification>
    <studytitle>A phase III randomized study with Paclitaxel (Taxol) and Gemcitabine or Vinorelbine in patients with stage IIIBw - IV non-operable non-small cell lung cancer (NSCLC), performance status (PS) 0,1.</studytitle>
    <scientifictitle>The comparative effect of combination  chemotherapy with Paclitaxel (Taxol) and Gemcitabine vs Taxol and Vinorelbine on survival in non-operable non-small cell lung cancer stage IIIBw and IV, PS : 0, 1. A Phase III randomized study.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Non-Small Cell Lung Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>GROUP B
Days 1, 8, 15
Taxol: 80mg/m2 in Normal Saline (N/S)  0.9% in 3h infusion followed premedication.
Vinorelbine : 22.5mg/m2 in 10 minute infusion followed by vein washing with normal saline.
Vinorelbine will be given first followed by Taxol.
Treatment will be repeated every 4 weeks for a total of 4 cycles
No  growth  factor  routinely  will  be  given  and  antiemetic  h² blockers (H2-receptor antagonists)  will  be  used  accordingly .</interventions>
    <comparator>GROUP A
Day 1
Taxol : 200 mg/m2 in Normal Saline (N/S) 0.9% as 3h infusion on day 1 with premedication.
Gemcitabine : 1000 mg/m2 in 500ml N/S as a 30min infusion.

Day 8
Gemcitabine : 1000 mg/m2 in 500ml N/S as a 30min infusion.
Treatment will be repeated every 3 weeks for a total of 4 cycles
No  growth  factor  routinely  will  be  given  and  antiemetic  h²  blockers  will  be  used  accordingly .</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Survival</outcome>
      <timepoint>1 year. 
This outcome is assessed using clinical data records</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Response</outcome>
      <timepoint>Response is assessed after 3 cycles of chemotherapy by imaging methods including computed tomography (CT) scan, bone scan, X-ray etc.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Progression (TTP)</outcome>
      <timepoint>After the end of treatment Progression is assessed every 3 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Progression (TTP)</outcome>
      <timepoint>After the end of treatment Progression is assessed every 3 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Toxicity</outcome>
      <timepoint>Toxicity is assessed after each cycle by laboratory evaluation of hematology and biochemistry, physical examination etc.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Histologically proven inoperable or recurrent or metastatic NSCLC stage IIIBw and IV. Biopsy, fine needle aspiration or sputum cytology will be used to obtain the samples.
Performance status 0, 1  of the Eastern Cooperative Oncology Group (ECOG) scale .
Measurable disease outside prior radiotherapy ports required , unless subsequent progression is documented .
Stable brain metastases . 
Prior surgery or radiotherapy is allowed .
Age  &gt; 18 years .
Life expectancy at least 12 weeks.
White Blood Cells (WBC) &gt; 4.000/ml or  platelets &gt; 100.000/ml, Bilirubin &lt; 1.2 mg/dl, gamma-glutamyltranspeptidase, alkaline phosphatase (ALP) normal, serum creatinine &lt; 1.4 mg/dl and creatinine clearance &gt; 60 ml/min.
Informed consent has to be signed.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Past or current history of neoplasm, except for Basal cell carcinoma of the skin or carcinoma in situ of the cervix.
Previous treatment with chemotherapy for recurrent or metastatic disease. 
History of atrial or ventricular arrhythmias, congestive heart failure even if medically controlled. Documented myocardial infarction. 
Pre  existing motor or sensory neurotoxicity grade &gt;2 according to World Health Organisation (WHO) scale (intolerable paresthesias and/or marked motor loss , or worse).  
Active infection or other serious underlying medical condition which would impair the ability of the patient to receive protocol treatment .</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>29/06/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>441</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Greece</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>Hellenic Cooperative Oncology Group</primarysponsorname>
    <primarysponsoraddress>18, Hatzikostandi str, 11524 Athens</primarysponsoraddress>
    <primarysponsorcountry>Greece</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>Hellenic Cooperative Oncology Group</fundingname>
      <fundingaddress>18, Hatzikostandi str, 11524 Athens</fundingaddress>
      <fundingcountry>Greece</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a prospective randomized phase III study comparing Paclitaxel and Gemcitabine with Paclitaxel and Vinorelbine in the treatment of patients with advanced non  operable non-small cell lung cancer (NSCLC).
Patients are randomized into two groups: Group A receive Gemcitabine on days 1 and 8 and Paclitaxel on day 1, every 3 weeks. 
Group B receive: Paclitaxel and Vinorelbine  on days 1, 8, 15 every 4 weeks. 
Both regimens will be given for 4 cycles.
The following parameters will be evaluated:
Survival, Time to progression, Response rates, Toxicity</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Paris Kosmidis</name>
      <address>2nd Department of Medical Oncology, Hygeia Hospital, Kifisias Av &amp; Er. Stavrou 4, 15123 Athens</address>
      <phone>+302106867105</phone>
      <fax />
      <email>parkosmi@otenet.gr</email>
      <country>Greece</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Eleni Papakostaki</name>
      <address>Hellenic Cooperative Oncology Group, 18 Hatzikostandi str, 11524, Athens</address>
      <phone>+302106912520</phone>
      <fax>+302106912713</fax>
      <email>hecogoff@otenet.gr; e_papakostaki@hecog.ondsl.gr</email>
      <country>Greece</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Maria Moschoni</name>
      <address>Hellenic Cooperative Oncology Group, 18 Hatzikostandi str, Athens, 11524</address>
      <phone>+302106912520</phone>
      <fax>+302106912713</fax>
      <email>hecogoff@otenet.gr</email>
      <country>Greece</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>